These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 23612971

  • 1. The von Hippel-Lindau protein pVHL inhibits ribosome biogenesis and protein synthesis.
    Zhao WT, Zhou CF, Li XB, Zhang YF, Fan L, Pelletier J, Fang J.
    J Biol Chem; 2013 Jun 07; 288(23):16588-16597. PubMed ID: 23612971
    [Abstract] [Full Text] [Related]

  • 2. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.
    Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ, Maxwell PH.
    J Biol Chem; 2000 Aug 18; 275(33):25733-41. PubMed ID: 10823831
    [Abstract] [Full Text] [Related]

  • 3. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
    Jung YS, Lee SJ, Yoon MH, Ha NC, Park BJ.
    Cell Cycle; 2012 Dec 01; 11(23):4462-73. PubMed ID: 23159849
    [Abstract] [Full Text] [Related]

  • 4. Hypoxia and cell cycle regulation of the von Hippel-Lindau tumor suppressor.
    Liu W, Xin H, Eckert DT, Brown JA, Gnarra JR.
    Oncogene; 2011 Jan 06; 30(1):21-31. PubMed ID: 20802534
    [Abstract] [Full Text] [Related]

  • 5. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
    Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.
    Cancer Res; 2002 Jul 01; 62(13):3803-11. PubMed ID: 12097293
    [Abstract] [Full Text] [Related]

  • 6. Diverse effects of mutations in exon II of the von Hippel-Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL-dependent ubiquitin ligase activity.
    Hansen WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG, Welch WJ.
    Mol Cell Biol; 2002 Mar 01; 22(6):1947-60. PubMed ID: 11865071
    [Abstract] [Full Text] [Related]

  • 7. pVHL mediates K63-linked ubiquitination of nCLU.
    Xue J, Lv DD, Jiao S, Zhao W, Li X, Sun H, Yan B, Fan L, Hu RG, Fang J.
    PLoS One; 2012 Mar 01; 7(4):e35848. PubMed ID: 22532874
    [Abstract] [Full Text] [Related]

  • 8. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 9. von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays.
    Galbán S, Fan J, Martindale JL, Cheadle C, Hoffman B, Woods MP, Temeles G, Brieger J, Decker J, Gorospe M.
    Mol Cell Biol; 2003 Apr 04; 23(7):2316-28. PubMed ID: 12640117
    [Abstract] [Full Text] [Related]

  • 10. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease.
    Clifford SC, Cockman ME, Smallwood AC, Mole DR, Woodward ER, Maxwell PH, Ratcliffe PJ, Maher ER.
    Hum Mol Genet; 2001 May 01; 10(10):1029-38. PubMed ID: 11331613
    [Abstract] [Full Text] [Related]

  • 11. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 May 01; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 12. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW, Ratcliffe PJ.
    Semin Cancer Biol; 2003 Feb 01; 13(1):83-9. PubMed ID: 12507560
    [Abstract] [Full Text] [Related]

  • 13. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor.
    Nyhan MJ, O'Sullivan GC, McKenna SL.
    Biochem Soc Trans; 2008 Jun 01; 36(Pt 3):472-8. PubMed ID: 18481984
    [Abstract] [Full Text] [Related]

  • 14. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein.
    Corn PG, McDonald ER, Herman JG, El-Deiry WS.
    Nat Genet; 2003 Nov 01; 35(3):229-37. PubMed ID: 14556007
    [Abstract] [Full Text] [Related]

  • 15. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C, Peng Z, Zhu M, Wang P, Du X, Li X, Liu Y, Jin Y, McNutt MA, Yin Y.
    Oncotarget; 2016 Sep 13; 7(37):60519-60534. PubMed ID: 27517496
    [Abstract] [Full Text] [Related]

  • 16. The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR.
    Zhou L, Yang H.
    PLoS One; 2011 Sep 13; 6(9):e23936. PubMed ID: 21949687
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
    Kaelin WG.
    Cold Spring Harb Symp Quant Biol; 2005 Sep 13; 70():159-66. PubMed ID: 16869749
    [Abstract] [Full Text] [Related]

  • 20. Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.
    Li Z, Wang D, Na X, Schoen SR, Messing EM, Wu G.
    Biochem Biophys Res Commun; 2002 Jun 14; 294(3):700-9. PubMed ID: 12056827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.